SLC5A2 and diabetic kidney disease: In the comparison between these UKPDS findings during 10 years of observation and the constant findings of SGLT2 inhibitors during 2 to 4 years of observations, however, SGLT2 inhibitors seem to have specific functions for the prevention of diabetic nephropathy (DN) and HF in T2DM patients independent of glycemic control [6, 10, 11].